Use of Lidocaine in Rapid Sequence Induction

National and Kapodistrian University of Athens

Status: Completed

Conditions: Hemodynamic Response

Treatments: Drug: Placebo; Drug: Lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT01238718

lidocaine3

Details and patient eligibility

About

Lidocaine has been shown to blunt the cardiovascular response to endotracheal intubation. The incidence of hypertension, tachycardia and dysrhythmias due to laryngoscopy may be increased in patients that receive rapid sequence induction and intubation, where opioids are spared and intravenous anesthetic agents are not titrated step by step. Our hypothesis was that lidocaine when administered intravenously in patients who undergo rapid sequence induction may not only blunt the hemodynamic response to intubation, but may also increase the anesthetic depth (as assessed by BIS), thus further reducing the possibility of hypertension, arrhythmias and also awareness.

Enrollment: 76 estimated patients

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• reason for rapid sequence induction (emergency, reflux),
• ASA I-II,
• no antihypertensive drugs,
• no antiarrhythmic drugs

Exclusion Criteria :

Trial design

76 participants in 2 patient groups, including a placebo group

lidocaine

Active Comparator group

Treatment:

Drug: Lidocaine

normal saline

Placebo Comparator group

Treatment:

Drug: Placebo